<DOC>
	<DOCNO>NCT01577745</DOCNO>
	<brief_summary>This first-time-in-human , Phase 1 , multicenter , open-label , single-arm , dose-escalation ( 3+3 ) study evaluate safety , tolerability , antitumor activity , PK immunogenicity MEDI0639 .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Safety , Tolerability , Pharmacokinetics MEDI0639 Advanced Solid Tumors</brief_title>
	<detailed_description>This first-time-in-human , Phase 1 , multicenter , open-label , single-arm , dose-escalation ( 3+3 ) study evaluate safety , tolerability , antitumor activity , PK , immunogenicity MEDI0639 adult subject advance solid tumor refractory standard therapy standard therapy exist . Up 63 subject enrol approximately 3 5 study center North America .</detailed_description>
	<criteria>Histologically cytologically confirm solid tumor refractory standard therapy standard therapy exist Age ≥ 18 year ECOG Performance Status 0 1 LVEF ( measure Echocardiogram ) &gt; 50 % No gastrointestinal bleeding within 1 year study entry . Adequate organ marrow function : Hemoglobin ≥ 10g/dL Absolute Neutrophil Count ≥ 1500/mm3 Platelet Count ≥ 100,000/mm3 AST &amp; ALT ≤ 2.5 x ULN Bilirubin ≤ 1.5 x ULN Cr Cl ≥ 50 mL/min ( determine CockcroftGault equation 24hour urine collection ) Prior therapy VEGF VEGFRs include , limited bevacizumab , sunitinib , sorafenib , pazopanib , motesanib ( AMG706 ) , cediranib ( AZD2171 ) , permit long agent know activity DLL4 last dose receive least 6 week prior first dose MEDI0639 . Life expectancy ≥ 12 week Females childbearing potential must surgically sterile , sterile male partner , premenarchal least 2 year postmenopausal , practice abstinence otherwise must use 2 effective method contraception time initiation investigational product . Males , unless surgically sterile , must use 2 effective method contraception female partner must agree continue use contraception 90 day last dose MEDI0639 Concurrent enrollment another investigational clinical study Receipt investigational anticancer therapy within 4 week prior first dose MEDI0639 case monoclonal antibody , 6 week prior first dose MEDI0639 Concurrent previous treatment inhibitor DLL4 Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic hormonal therapy cancer treatment Known bleeding diathesis , esophageal varix , angioplasty Pulmonary hemorrhage gross hemoptysis within 12 month Known arterial venous thrombosis pulmonary embolism within 2 year Concurrent use systemic low molecular weight heparin low dose warfarin Presence brain metastasis Cerebrovascular accident transient ischemic attack within 2 year Cardiovascular event , myocardial infarction , unstable/severe angina , coronary/peripheral artery bypass graft , unstable cardiac arrhythmia require medication , congestive heart failure ( NYHA &gt; class II ) , within 2 year Tumors squamous cell histology Major surgical procedure within 90 day Pregnancy lactation Known HIV positive Hepatitis A , B , C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cancer</keyword>
</DOC>